Five factor model of schizophrenia: replication across samples
- PMID: 7766534
- DOI: 10.1016/0920-9964(94)00041-6
Five factor model of schizophrenia: replication across samples
Abstract
In order to examine the effect of neuroleptic medication on the factor structure of schizophrenic symptomatology, 517 DSM-III-R schizophrenic in-patients enrolled in a multicenter phase II drug study were evaluated on their pre-existing neuroleptic at screening on the Positive and Negative Syndrome Scale (PANSS) and after a one-week drug-free period. Separate principal components analyses of the PANSS were done at each time point. PANSS total and component scores were assessed for differences utilizing paired t-tests. Both factor analyses confirmed the five factor model (negative, positive, cognitive, excitement and depression components) explaining 51.7 and 56.2% of the variances at each time point. After medication wash-out psychopathology significantly worsened as measured by total PANSS score and by each of the components. The overall worsening of component scores appeared global and uniform, as evidenced by the fact that at washout, the proportion of individual component scores to total psychopathology remained constant for most components. The lack of change of most components in proportion to the psychopathology total is evidence for the stability of these individual psychopathological dimensions of patients while on and off neuroleptics. The results further support the validity of the five-factor model of schizophrenic psychopathology as measured by the PANSS.
Similar articles
-
A forced five-dimensional factor analysis and concurrent validity of the Positive and Negative Syndrome Scale in Mexican schizophrenic patients.Schizophr Res. 2005 Jan 1;72(2-3):123-9. doi: 10.1016/j.schres.2004.03.021. Schizophr Res. 2005. PMID: 15560957
-
Five-factor model of schizophrenic psychopathology: how valid is it?Eur Arch Psychiatry Clin Neurosci. 2000;250(2):93-100. doi: 10.1007/s004060070041. Eur Arch Psychiatry Clin Neurosci. 2000. PMID: 10853925
-
An excitement subscale of the Positive and Negative Syndrome Scale.Schizophr Res. 2004 Jun 1;68(2-3):331-7. doi: 10.1016/S0920-9964(03)00087-2. Schizophr Res. 2004. PMID: 15099614
-
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?J Clin Psychiatry. 1999;60 Suppl 5:23-9; discussion 30. J Clin Psychiatry. 1999. PMID: 10192404 Review.
-
Latent structures underlying schizophrenic symptoms: a five-dimensional model.Schizophr Res. 1999 Aug 23;39(1):39-50. doi: 10.1016/s0920-9964(99)00018-3. Schizophr Res. 1999. PMID: 10480666 Review.
Cited by
-
History of religious delusions and psychosocial functioning among Mexican patients with paranoid schizophrenia.J Relig Health. 2014 Dec;53(6):1622-33. doi: 10.1007/s10943-013-9727-9. J Relig Health. 2014. PMID: 23674244
-
Patterns of schizophrenia symptoms: hidden structure in the PANSS questionnaire.Transl Psychiatry. 2018 Oct 30;8(1):237. doi: 10.1038/s41398-018-0294-4. Transl Psychiatry. 2018. PMID: 30375374 Free PMC article.
-
A review of risky decision-making in psychosis-spectrum disorders.Clin Psychol Rev. 2022 Feb;91:102112. doi: 10.1016/j.cpr.2021.102112. Epub 2021 Dec 20. Clin Psychol Rev. 2022. PMID: 34990988 Free PMC article. Review.
-
Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled trial (a Positive and Negative Syndrome Scale, five-factor analysis).Psychopharmacology (Berl). 2015 Jan;232(1):155-64. doi: 10.1007/s00213-014-3645-8. Epub 2014 Jun 13. Psychopharmacology (Berl). 2015. PMID: 24923986 Clinical Trial.
-
Accelerated neurostimulation protocols for auditory hallucinations: a systematic review and meta-analysis.Front Psychiatry. 2025 Jun 13;16:1491487. doi: 10.3389/fpsyt.2025.1491487. eCollection 2025. Front Psychiatry. 2025. PMID: 40585540 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical